These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8743336)

  • 21. Clinical pharmacokinetics of fluconazole in superficial and systemic mycoses.
    Debruyne D
    Clin Pharmacokinet; 1997 Jul; 33(1):52-77. PubMed ID: 9250423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinical pharmacokinetics of levofloxacin.
    Fish DN; Chow AT
    Clin Pharmacokinet; 1997 Feb; 32(2):101-19. PubMed ID: 9068926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical pharmacokinetics of beta-adrenoreceptor blocking drugs.
    Johnsson G; Regàrdh CG
    Clin Pharmacokinet; 1976; 1(4):233-63. PubMed ID: 13958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
    Wåhlander K; Eriksson-Lepkowska M; Frison L; Fager G; Eriksson UG
    Clin Pharmacokinet; 2003; 42(8):755-64. PubMed ID: 12846596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Anti-ischemic effects of SIN-1, a molsidomine metabolite, during coronary angioplasty and antiplatelet effects in humans].
    Darius H; Erbel E; Schmucker B; Reusch U; Meyer J
    Presse Med; 1988 May; 17(20):1033-6. PubMed ID: 2969099
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics of intravenous levosimendan and its metabolites in subjects with hepatic impairment.
    Puttonen J; Kantele S; Ruck A; Ramela M; Häkkinen S; Kivikko M; Pentikäinen PJ
    J Clin Pharmacol; 2008 Apr; 48(4):445-54. PubMed ID: 18303124
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of nicorandil.
    Frydman AM; Chapelle P; Diekmann H; Bruno R; Thebault JJ; Bouthier J; Caplain H; Ungethuem W; Gaillard C; Le Liboux A
    Am J Cardiol; 1989 Jun; 63(21):25J-33J. PubMed ID: 2525322
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-dose morphine and methadone in cancer patients. Clinical pharmacokinetic considerations of oral treatment.
    Säwe J
    Clin Pharmacokinet; 1986; 11(2):87-106. PubMed ID: 3514045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-acting coronary vasodilatory action of the molsidomine metabolite Sin 1: a quantitative angiographic study.
    Serruys PW; Deckers JW; Luijten HE; Reiber JH; Tijssen JG; Chadha D; Hugenholtz PG
    Eur Heart J; 1987 Mar; 8(3):263-70. PubMed ID: 3582385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparative course of maintenance of the effects of nitrite derivatives and molsidomine after prolonged administration].
    Weber S; Degeorges M
    Presse Med; 1988 May; 17(20):992-5. PubMed ID: 2969104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Ergometric study of a new vasodilator agent in angina: molsidomine. Value of combination with beta-blockaders].
    Witchitz S; Kolsky H; Moisson P; Valette H
    Arch Mal Coeur Vaiss; 1981 Apr; 74(4):463-71. PubMed ID: 6112971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical pharmacokinetics of candesartan.
    Gleiter CH; Mörike KE
    Clin Pharmacokinet; 2002; 41(1):7-17. PubMed ID: 11825094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The clinical pharmacokinetics of famciclovir.
    Gill KS; Wood MJ
    Clin Pharmacokinet; 1996 Jul; 31(1):1-8. PubMed ID: 8827396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effect duration and dose-response relation of molsidomine in patients with coronary heart disease].
    Fach WA; Becker HJ
    Z Kardiol; 1984 Oct; 73(10):613-22. PubMed ID: 6393621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacokinetics of cimetidine.
    Somogyi A; Gugler R
    Clin Pharmacokinet; 1983; 8(6):463-95. PubMed ID: 6418428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical pharmacokinetics of mizolastine.
    Lebrun-Vignes B; Diquet B; Chosidow O
    Clin Pharmacokinet; 2001; 40(7):501-7. PubMed ID: 11510627
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients.
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2007; 46(1):13-58. PubMed ID: 17201457
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Molsidomine in chronic heart failure with liver congestion--oral or intravenous therapy?].
    Grosse-Heitmeyer W; Huber T; Ostrowski J
    Med Klin (Munich); 1993 Jan; 88(1):21-5. PubMed ID: 8437528
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of molsidomine once-a-day in patients with stable angina pectoris.
    Messin R; Opolski G; Fenyvesi T; Carreer-Bruhwyler F; Dubois C; Famaey JP; Géczy J
    Int J Cardiol; 2005 Jan; 98(1):79-89. PubMed ID: 15676171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.